Try
Caris Life Sciences, Inc.
CAIUnited States
10 filed reports · 327 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
10 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 14 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 5 | 14 | Jun 2025 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 4 | 1,021 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 996 | Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 349 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 8, 2026 | 214 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 4 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 3, 2026 | 996 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 26, 2026 | 2 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 5, 2025 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 288 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 12, 2025 | 170 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 12, 2025 | 2 | Open |
Financial data
327 concepts · 2,031 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial310 concepts · 1,818 facts · Dec 2023 to Aug 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations13 · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)13 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Dec 2023 to Jun 2026
- Adjustments to revenue related to services delivered in prior periods12 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Amortization of debt discount premium12 · Dec 2023 to Jun 2026
- Changes in fair value of financial instruments12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Costs and expenses12 · Dec 2023 to Jun 2026
- Depreciation depletion and amortization12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense debt12 · Dec 2023 to Jun 2026
- Interest expense debt excluding amortization12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Interest income other12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Net income loss available to common stockholders basic12 · Dec 2023 to Jun 2026
- Net income loss available to common stockholders diluted12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
Segment12 concepts · 127 facts · Dec 2023 to Dec 2025
- Revenue23 · Dec 2023 to Dec 2025
- Cost of goods and services sold (US GAAP)18 · Dec 2023 to Dec 2025
- Changes in fair value of financial instruments9 · Dec 2023 to Dec 2025
- General and administrative expense (US GAAP)9 · Dec 2023 to Dec 2025
- Interest expense nonoperating9 · Dec 2023 to Dec 2025
- Interest income other9 · Dec 2023 to Dec 2025
- Net income loss9 · Dec 2023 to Dec 2025
- Other nonoperating income expense9 · Dec 2023 to Dec 2025
- Research and development expense9 · Dec 2023 to Dec 2025
- Selling and marketing expense (US GAAP)9 · Dec 2023 to Dec 2025
- Costs and expenses7 · Dec 2023 to Dec 2025
- Operating income loss7 · Dec 2023 to Dec 2025
Product2 concepts · 48 facts · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)24 · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
Geography1 concepts · 24 facts · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
Guidance2 concepts · 14 facts · Aug 2025 to Aug 2026
- Revenue Guidance10 · Aug 2025 to Aug 2026
- Revenue Growth Guidance4 · May 2026 to Aug 2026
Segments
199 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 127 facts
- Reportable127 · Dec 2023 to Dec 2025
Product or service2 members · 48 facts
- Molecular Profiling Services24 · Dec 2023 to Jun 2026
- Pharma Research And Development Services24 · Dec 2023 to Jun 2026
Statement geographical2 members · 24 facts
- Non Us12 · Dec 2023 to Jun 2026
- US12 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.